-
公开(公告)号:US20140107343A1
公开(公告)日:2014-04-17
申请号:US14105395
申请日:2013-12-13
申请人: Bo QU , Anjan SAHA , Jolaine SAVOIE , Xudong WEI , Nathan K. YEE
发明人: Bo QU , Anjan SAHA , Jolaine SAVOIE , Xudong WEI , Nathan K. YEE
IPC分类号: C07D221/16 , C07D213/57
CPC分类号: C07D221/16 , C07D213/57 , C07D221/06
摘要: Disclosed is a compound of formula (I) and salts thereof. Also disclosed are methods of making the compound of formula (I) and the use of the compound as an intermediate for making pharmaceutically active compounds such as 11-β-hydroxysteroid hydrogenase type 1 (11-β-HSD1) inhibitors.
摘要翻译: 公开了式(I)的化合物及其盐。 还公开了制备式(I)化合物的方法和该化合物作为中间体用于制备药学活性化合物如11-羟基类固醇类氢化酶1型(11-bgr-HSD1)抑制剂的方法。
-
公开(公告)号:US20090124809A1
公开(公告)日:2009-05-14
申请号:US12355157
申请日:2009-01-16
申请人: Carl Alan BUSACCA , Rogelio Perez FRUTOS , Nizar HADDAD , Suresh R. KAPADIA , Jon Charles LORENZ , Anjan SAHA , Chris Hugh SENANAYAKE , Xudong WEI
发明人: Carl Alan BUSACCA , Rogelio Perez FRUTOS , Nizar HADDAD , Suresh R. KAPADIA , Jon Charles LORENZ , Anjan SAHA , Chris Hugh SENANAYAKE , Xudong WEI
IPC分类号: C07D417/14 , C07C225/22
CPC分类号: C07K5/0808 , C07C225/22 , C07D417/14
摘要: Disclosed are highly convergent processes for preparing compounds of formula (I), which compounds are potent active agents for the treatment of hepatitis C virus (HCV) infection: The disclosed processes use SNAr-type coupling reactions between peptidic compounds having a hydroxyproline moiety of the following formula: and halogenated or sulfonated bromoquinoline compounds.
-
公开(公告)号:US20090124808A1
公开(公告)日:2009-05-14
申请号:US12355150
申请日:2009-01-16
申请人: Carl Alan BUSACCA , Rogelio Perez FRUTOS , Nizar HADDAD , Suresh R. KAPADIA , Jon Charles LORENZ , Anjan SAHA , Chris Hugh SENANAYAKE , Xudong WEI
发明人: Carl Alan BUSACCA , Rogelio Perez FRUTOS , Nizar HADDAD , Suresh R. KAPADIA , Jon Charles LORENZ , Anjan SAHA , Chris Hugh SENANAYAKE , Xudong WEI
IPC分类号: C07D417/14
CPC分类号: C07K5/0808 , C07C225/22 , C07D417/14
摘要: Disclosed are highly convergent processes for preparing compounds of formula (I), which compounds are potent active agents for the treatment of hepatitis C virus (HCV) infection: The disclosed processes use SNAr-type coupling reactions between peptidic compounds having a hydroxyproline moiety of the following formula: and halogenated or sulfonated bromoquinoline compounds.
摘要翻译: 公开了用于制备式(I)化合物的高度收敛的方法,该化合物是用于治疗丙型肝炎病毒(HCV)感染的有效活性剂:所公开的方法使用具有羟丙基部分的肽化合物之间的SNAr-型偶联反应 以下公式:卤代或磺化溴喹啉化合物。
-
公开(公告)号:US20130244996A1
公开(公告)日:2013-09-19
申请号:US13785034
申请日:2013-03-05
申请人: Asitha ABEYWARDANE , Steven Richard BRUNETTE , Michael J. BURKE , Suresh R. KAPADIA , Thomas Martin KIRRANE , Matthew Russell NETHERTON , Hossein RAZAVI , Sonia RODRIGUEZ , Anjan SAHA , Robert SIBLEY , Lana Louise SMITH-KEENAN , Hidenori TAKAHASHI , Michael Robert TURNER , Jiang-Ping WU , Erick Richard Roush YOUNG , Qiang ZHANG , Qing ZHANG , Renee M. ZINDELL
发明人: Asitha ABEYWARDANE , Steven Richard BRUNETTE , Michael J. BURKE , Suresh R. KAPADIA , Thomas Martin KIRRANE , Matthew Russell NETHERTON , Hossein RAZAVI , Sonia RODRIGUEZ , Anjan SAHA , Robert SIBLEY , Lana Louise SMITH-KEENAN , Hidenori TAKAHASHI , Michael Robert TURNER , Jiang-Ping WU , Erick Richard Roush YOUNG , Qiang ZHANG , Qing ZHANG , Renee M. ZINDELL
IPC分类号: C07D491/052 , C07D513/04 , C07D295/155 , C07D405/10 , C07D295/096
CPC分类号: C07D491/052 , A61K31/357 , C07D295/096 , C07D295/155 , C07D319/20 , C07D405/10 , C07D405/12 , C07D405/14 , C07D413/10 , C07D417/10 , C07D417/14 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/04 , C07D513/04 , C07D519/00
摘要: The present invention relates to compounds of formula (I): wherein R1 to R3, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.
摘要翻译: 本发明涉及式(I)的化合物:其中R1至R3,A,X和n如本文所定义。 式(I)化合物可用作白三烯A4水解酶(LTA4H)的抑制剂和治疗LTA4H相关病症。 本发明还涉及包含式(I)化合物的药物组合物,使用这些化合物治疗各种疾病和病症的方法,以及制备这些化合物的方法。
-
-
-